Header and Body 3


CRISPR/Cas( has been used in genome-wide mutation screens to identify genes required for survival, drug resistance, and tumor metastasis. MERA improves upon this previous gene mutation screening approach by ensuring cells receive a precise number of guide RNA (gRNA) per cell (i.e., one or more than one for combinatorial studies) and allows for gRNA libraries to be used without any laborious molecular cloning into a delivery vector. These methods can be used to screen for the effect of mutations anywhere in the genome.